87
Participants
Start Date
March 5, 2021
Primary Completion Date
April 30, 2024
Study Completion Date
August 27, 2024
Surufatinib and Tislelizumab _ Part 1
Part 1 (all cohorts): oral surufatinib at a dose based on cohort level and intravenous tislelizumab at a 200-mg dose
Surufatinib and Tislelizumab _ Part 2
Part 2 (all cohorts): oral surufatinib at the RP2D dose selected in Part 1 and intravenous tislelizumab at a 200-mg dose
Memorial Sloan Kettering Cancer Center, New York
University of Pennsylvania, Perelman Center for Advanced Medicine, Philadelphia
Johns Hopkins University - Sibley Memorial Hospital, Washington D.C.
Virginia Cancer Specialists, PC, Fairfax
Prisma Health - Upstate (ITOR), Greenville
Emory University - Winship Cancer Institute, Atlanta
Sarah Cannon, Nashville
Vanderbilt University Medical Center, Nashville
University Hospitals Cleveland Medical Center, Cleveland
Holden Comprehensive Cancer Center, University of Iowa, Iowa City
Mary Crowley Cancer Research, Dallas
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
Texas Oncology, P.A., Tyler
Texas Oncology, P.A., Fort Worth
The University of Texas MD Anderson Cancer Center, Houston
Rocky Mountain Cancer Centers Midtown, Denver
Arizona Oncology Associated, PC-HOPE, Tucson
City of Hope, Duarte